InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (2 ops.)
Browse the detailed record of transactions filed by Scopa James Paul, Director. Officer active across 2 companies, notably DICE Therapeutics, Inc.. Cumulatively, 4 disclosures have been published. Total volume traded: €363k. The latest transaction was filed on 15 November 2021 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations4 total
€95,26650,000 shares@ €1.9053100.0% of flow
Common Stock
SEC:0001209191-21-065115·
€95,26650,000 shares@ €1.905350.0% of flow
Common Stock
SEC:0001209191-21-065115:0·
€86,2946,000 shares@ €14.3824100.0% of flow
Common Stock
SEC:0001209191-21-056526·
Ideal exit: 12 Jun 2022 (T+270)
€86,2946,000 shares@ €14.382450.0% of flow
Common Stock
SEC:0001209191-21-056526:0·
Ideal exit: 12 Jun 2022 (T+270)
4 of 4 declarations
About Scopa James Paul
James Paul Scopa is a Board Member at DICE Therapeutics, Inc. and Adverum Biotechnologies, Inc. He participates in overseeing operations and strategic decision-making for both companies. James brings expertise in biotechnology, contributing to the innovation and growth of these firms.
